|
| |
Thrombotargets Corp. and Chemotargets to collaborate on identification of
novel hits related with cardiovascular diseases
Companies Sign a Collaborative Agreement. Durham, June 1st, 2007.
Thrombotargets Corporation and Chemotargets today announced the formation of
drug discovery collaboration.
Under the terms of this agreement, Chemotargets will apply its in silico target
profiling platform to identify potential novel hits for some targets associated
with cardiovascular diseases that will be subsequently screened at
Thrombotargets using its proprietary High Throughput Screening for Pathway
Activity, BIOPLATFORMSCREEN™ technology.
Thrombotargets ( www.thrombotargets.com
) is a privately held group of Biotech companies focused in the discovery and
development of innovative drugs in Haemostasis, Thrombosis and Atherosclerosis.
The company has a number of potential new drugs in development internally, and
its proprietary targets and innovative uHTS platforms are used for internal drug
discovery programs, and also for out-licensing and partnering of new research
projects.
Chemotargets ( www.chemotargets.com )
is a Barcelona based in silico pharmacology company that has developed a
pharmacology platform able to design chemical libraries directed to particular
sets of disease-related targets or entire protein families, identifying new
chemical entities with customised affinity profiles, or identifying potential
off-targets at which compounds designed for a particular target may have
residual affinity (target fishing).
ABOUT THROMBOTARGETS GROUP
Thrombotargets group is comprised by three companies; Thrombotargets
Corporation (Durham, NC, USA) is responsible for Drug Development and Business
Development; Thrombotargets Europe (Barcelona, Spain) for Target Identification,
Lead validation and Lead optimization and Biotech Libraries (Spain) for
engineered targeted libraries and High Throughput Screening.
Thrombotargets has developed and adapted to High Throughput Screening, a new
family of biological assays, Hemosta-BIOPLATFORMSCREEN™, capable to quantify
simultaneously clot formation and clot lysis , Oxidant- BIOPLATFORMSCREEN™ to
quantify total antioxidant capacity and Athero- BIOPLATFORMSCREEN™, to quantify
low-density lipoprotein modification. With these proven proprietary new HTS
Platforms (BIOPLATFORMSCREEN™), Thrombotargets group is creating a continuously
novel and promising pipeline of drug candidates. TT-103MH, Thrombotargets’ most
advanced drug candidate, has recently been granted with an Orphan Drug
Designation.
Contact:
Luis Caveda Ph.D.
Thrombotargets Corp.
COO
luiscaveda@thrombotargets.com
| |
|
